These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1609044)

  • 1. Effects of phosphatidylserine in Alzheimer's disease.
    Crook T; Petrie W; Wells C; Massari DC
    Psychopharmacol Bull; 1992; 28(1):61-6. PubMed ID: 1609044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphatidylserine in the treatment of clinically diagnosed Alzheimer's disease. The SMID Group.
    J Neural Transm Suppl; 1987; 24():287-92. PubMed ID: 3479526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study.
    Amaducci L
    Psychopharmacol Bull; 1988; 24(1):130-4. PubMed ID: 3290936
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
    Antuono PG
    Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease.
    Clipp EC; Moore MJ
    Clin Pharmacol Ther; 1995 Aug; 58(2):228-36. PubMed ID: 7648773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
    Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
    Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noradrenergic intervention in Alzheimer's disease.
    Crook T; Wilner E; Rothwell A; Winterling D; McEntee W
    Psychopharmacol Bull; 1992; 28(1):67-70. PubMed ID: 1609045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lisuride treatment of Alzheimer's disease. A preliminary placebo-controlled clinical trial of safety and therapeutic efficacy.
    Claus JJ; de Koning I; van Harskamp F; Breteler MM; Voet B; Gutzmann H; Dahlke F; van der Cammen T; Hofman A
    Clin Neuropharmacol; 1998; 21(3):190-5. PubMed ID: 9617511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
    Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
    Chiu CC; Su KP; Cheng TC; Liu HC; Chang CJ; Dewey ME; Stewart R; Huang SY
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1538-44. PubMed ID: 18573585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open trial of plant-source derived phosphatydilserine for treatment of age-related cognitive decline.
    Schreiber S; Kampf-Sherf O; Gorfine M; Kelly D; Oppenheim Y; Lerer B
    Isr J Psychiatry Relat Sci; 2000; 37(4):302-7. PubMed ID: 11201936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
    Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
    Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men.
    Lu PH; Masterman DA; Mulnard R; Cotman C; Miller B; Yaffe K; Reback E; Porter V; Swerdloff R; Cummings JL
    Arch Neurol; 2006 Feb; 63(2):177-85. PubMed ID: 16344336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer's type (SDAT).
    Fünfgeld EW; Baggen M; Nedwidek P; Richstein B; Mistlberger G
    Prog Clin Biol Res; 1989; 317():1235-46. PubMed ID: 2690093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D; Andersen HF
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.